With data like these in hand, why would they still include 24-week arms in fixed dose combination with or without RBV in ION-1 and ION-2 ph3 trials? There's a option to discontinue treatment at 12-weeks. I'm not sure if this option extends to all ION cohorts.
Market Data 
Markets
AI
